Sector News

Lilly moves forward with biologics plant expansion that will add 130 jobs

May 9, 2017
Life sciences

The on-again, off-again $215 million expansion of an Eli Lilly biologics plant in Ireland is on again.

The Indianapolis, Indiana-based company said Monday it will move forward with plans to add a manufacturing line at its site in Kindsdale, County Cork. It said construction should begin in coming months and commissioning will begin in 2019. The expansion is expected to add about 130 workers to the site by 2020.

Spokesperson Tamara Ann Hull said in an email that because negotiations are underway, specifics of the investment were not being released. Earlier reports put the cost at about €200 million.

Tremors of concern spread through Ireland in February when Lilly said it halted preparations for the project. That ignited speculation among some politicians that Lilly might divert funds to the U.S. after President Trump held a meeting with pharma execs in which he urged them to invest in U.S. manufacturing. Lilly’s new CEO David Ricks was at that meeting.

Weeks later, Ricks announced an $85 million expansion at an insulin device plant in Indianapolis and pointed to $850 million in capital outlays this year in the U.S. as an indicator of its commitment to investing there.

Lilly has been expanding its biopharma operations in Cork for some years. In 2012, it began construction of a 22,000-square-meter bioprocessing plant. It also has a 158,000-square-meter monoclonal antibody plant there that was completed in 2010.

The site also does API production for a host of small molecule drugs. Last year, the company said it would invest nearly $40 million (€35 million) to build a continuous manufacturing facility there. At the time it said it had invested about $740 million (€650 million) in the site in 8 years, hiring 350 employees.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”